000164058 001__ 164058
000164058 005__ 20230915090546.0
000164058 0247_ $$2doi$$a10.1038/s41531-022-00301-2
000164058 0247_ $$2pmid$$apmid:35440571
000164058 0247_ $$2pmc$$apmc:PMC9018912
000164058 0247_ $$2altmetric$$aaltmetric:126937397
000164058 037__ $$aDZNE-2022-00721
000164058 041__ $$aEnglish
000164058 082__ $$a610
000164058 1001_ $$00000-0003-1290-208X$$aFeldmann, Lucia K$$b0
000164058 245__ $$aToward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings.
000164058 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2022
000164058 3367_ $$2DRIVER$$aarticle
000164058 3367_ $$2DataCite$$aOutput Types/Journal article
000164058 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655118377_6957
000164058 3367_ $$2BibTeX$$aARTICLE
000164058 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164058 3367_ $$00$$2EndNote$$aJournal Article
000164058 520__ $$aAdaptive deep brain stimulation (aDBS) is a promising concept for feedback-based neurostimulation, with the potential of clinical implementation with the sensing-enabled Percept neurostimulator. We aim to characterize chronic electrophysiological activity during stimulation and to validate beta-band activity as a biomarker for bradykinesia. Subthalamic activity was recorded during stepwise stimulation amplitude increase OFF medication in 10 Parkinson's patients during rest and finger tapping. Offline analysis of wavelet-transformed beta-band activity and assessment of inter-variable relationships in linear mixed effects models were implemented. There was a stepwise suppression of low-beta activity with increasing stimulation intensity (p = 0.002). Low-beta power was negatively correlated with movement speed and predictive for velocity improvements (p < 0.001), stimulation amplitude for beta suppression (p < 0.001). Here, we characterize beta-band modulation as a chronic biomarker for motor performance. Our investigations support the use of electrophysiology in therapy optimization, providing evidence for the use of biomarker analysis for clinical aDBS.
000164058 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164058 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164058 7001_ $$aLofredi, Roxanne$$b1
000164058 7001_ $$00000-0002-6758-9708$$aNeumann, Wolf-Julian$$b2
000164058 7001_ $$00000-0003-0067-6177$$aAl-Fatly, Bassam$$b3
000164058 7001_ $$00000-0003-2814-3532$$aRoediger, Jan$$b4
000164058 7001_ $$00000-0003-1963-9798$$aBahners, Bahne H$$b5
000164058 7001_ $$aNikolov, Petyo$$b6
000164058 7001_ $$aDenison, Timothy$$b7
000164058 7001_ $$aSaryyeva, Assel$$b8
000164058 7001_ $$00000-0002-0675-9064$$aKrauss, Joachim K$$b9
000164058 7001_ $$aFaust, Katharina$$b10
000164058 7001_ $$00000-0001-8276-2508$$aFlorin, Esther$$b11
000164058 7001_ $$00000-0002-6414-7939$$aSchnitzler, Alfons$$b12
000164058 7001_ $$aSchneider, Gerd-Helge$$b13
000164058 7001_ $$0P:(DE-2719)2811089$$aKühn, Andrea A$$b14$$eLast author$$udzne
000164058 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-022-00301-2$$gVol. 8, no. 1, p. 44$$n1$$p44$$tnpj Parkinson's Disease$$v8$$x2373-8057$$y2022
000164058 8564_ $$uhttps://pub.dzne.de/record/164058/files/DZNE-2022-00721.pdf$$yOpenAccess
000164058 8564_ $$uhttps://pub.dzne.de/record/164058/files/DZNE-2022-00721.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164058 909CO $$ooai:pub.dzne.de:164058$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000164058 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811089$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000164058 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164058 9141_ $$y2022
000164058 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-03
000164058 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-03
000164058 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-03
000164058 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-03
000164058 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164058 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-03
000164058 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2021$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-13T14:34:28Z
000164058 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-13T14:34:28Z
000164058 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-10-13T14:34:28Z
000164058 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-03-31
000164058 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2021$$d2023-03-31
000164058 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lCoordinator of Clinical Research$$x0
000164058 980__ $$ajournal
000164058 980__ $$aVDB
000164058 980__ $$aUNRESTRICTED
000164058 980__ $$aI:(DE-2719)1811005
000164058 9801_ $$aFullTexts